Chargement des cours...

Prévisions

L'objectif de cours moyen des analystes est de 23,62 € (+120,13 %). La médiane est de 23,62 € (+120,13 %).

Acheter
  10
Conserver
  5
Vendre
  1

Discussions dans la communauté

Il n'y a pas encore de discussion sur cet actif.

Lancer une discussion

  • Novocure presents turnaround plan with profitability targets and product launches

    At the Morgan Stanley Healthcare Conference, Novocure unveiled a three-stage plan to achieve profitability and for the first time provided financial guidance, targeting adjusted EBITDA break-even by the end of 2025. The company reported 8% volume growth in its glioblastoma business, sees further upside in the US, and identifies Japan as its fourth-largest market. New product launches for pancreatic cancer (Optune Pax, CE mark in Europe) and non-small cell lung cancer are expected to drive growth; Novocure stresses it has roughly $440 million of liquidity to execute the plan. » Plus sur de.investing.com


  • NovoCure: market launches of Optune Pax gain momentum and drive international growth

    NovoCure reported at the Wells‑Fargo conference increasing commercial momentum, particularly for Optune Pax in pancreatic cancer with about 600 prescriptions in four months and roughly 285 active patients. The company generated positive cash flow in Q2 2026 for the first time in years and is targeting a clear path to profitability alongside double‑digit revenue growth. Growth drivers also include Optune Gio for glioblastoma and expansion in Japan; risks remain reimbursement, competition from adagrasib, and a recent cybersecurity incident with limited impact. NovoCure is keeping R&D spending around $200 million and plans to hold sales and marketing costs stable, while additional approvals and guideline inclusions should support uptake. » Plus sur de.investing.com


  • NovoCure shows revenue growth but remains cash-flow negative as it expands TTFields devices

    NovoCure’s Tumor Treating Fields devices, including Optune Gio and newly FDA-approved Optune Pax, drove revenue growth to about $655–704 million range, but the company posted a net loss (≈$136.2 million in FY2025) and negative free cash flow (−$75.7 million) as it invests in expansion. Debt and a near 0.9x debt-to-equity ratio, reliance on single-source suppliers, and expected negative free cash flow through 2027 pressure financing needs. Valuation looks more attractive than peer Omeros, but NovoCure faces execution and reimbursement risks that could limit near-term shareholder returns. » Plus sur finance.yahoo.com


  • Novocure shares fall after TRIDENT phase‑3 study – primary endpoint missed

    The TRIDENT phase‑3 trial by Novocure did not meet its primary endpoint in newly diagnosed glioblastoma: median overall survival 17.7 vs. 17.5 months (hazard ratio 0.953; p=0.519) in 981 patients. The result prevents a potential expansion of Optune Gio use into the earlier radiochemotherapy phase, which had been seen as an important growth driver. Consequently, the stock plunged in pre‑market trading, exacerbated by a risk‑averse market environment after signals from the Fed. » Plus sur de.investing.com


  • NovoCure CEO sells 34,273 shares for about $615,000

    Frank Leonard, CEO of NovoCure, reported an open-market sale of 34,273 common shares on June 4, 2026, for roughly $615,000. The sale reduced his direct holdings from 493,793 to 459,520 shares, representing 6.94% of his prior direct stake, and is his largest individual open-market sale to date. No indirect or derivative interests were affected; post-transaction direct holdings were valued at about $8.3 million. » Plus sur finance.yahoo.com

Données financières de l'entreprise

Au dernier trimestre, NovoCure a réalisé un chiffre d'affaires de 170,74 M € et un bénéfice net de -9,21 M €
(EUR) septembre 2026
YoY
Chiffre d'affaires 170,74 M 19,84 %
Bénéfice brut 131,43 M 25,93 %
Bénéfice net -9,21 M 70,99 %
EBITDA 1,84 M 108,18 %

Données fondamentales

Indicateur Valeur
Capitalisation boursière
1,26 Md €
Nombre d'actions
116,92 M
Plus haut/bas sur 52 semaines
19,48 € - 8,92 €
Dividendes Non
Bêta
1,08
Ratio P/E
-11,16
Ratio PEG
-0,42
Ratio P/B
3,94
Ratio P/S
1,91

Profil de l'entreprise

NovoCure Limited, une entreprise d'oncologie, est engagée dans le développement, la fabrication et la commercialisation de dispositifs à champs de traitement tumoral (TTFields) destinés au traitement des cancers solides dans les régions suivantes : États-Unis, Europe, Moyen-Orient, Afrique, Japon et Grande Chine. Ses dispositifs TTFields comprennent Optune, utilisé pour le traitement du glioblastome, et Optune Lua, utilisé pour le traitement du mésothéliome pleural malin. La société mène également des essais cliniques en cours ou achevés portant sur les TTFields dans les métastases cérébrales, le cancer gastrique, le glioblastome, le cancer du foie, le cancer du poumon non à petites cellules, le cancer du pancréas et le cancer de l'ovaire. NovoCure Limited a été constituée en 2000 et son siège social se situe à Saint-Hélier, à Jersey.

Nom
NovoCure
PDG
Frank Leonard
Siège social Baar,
Israël
Site web
Secteur
Santé
Industrie
Technologies de la santé
Introduction en bourse
01/10/2015
Employés 1 605

Symboles boursiers

Bourse Symbole
NASDAQ
NVCR
Frankfurt
038.F
Düsseldorf
038.DU
München
038.MU
🍪

Parqet  utilise des cookies. En savoir plus